1-(5-tert-Butyl-isoxazol-3-yl)-3-[4-(pyridin-4-yloxy)-phenyl]-urea

ID: ALA166031

Chembl Id: CHEMBL166031

PubChem CID: 9819877

Max Phase: Preclinical

Molecular Formula: C19H20N4O3

Molecular Weight: 352.39

Molecule Type: Small molecule

Names and Identifiers

Canonical SMILES:  CC(C)(C)c1cc(NC(=O)Nc2ccc(Oc3ccncc3)cc2)no1

Standard InChI:  InChI=1S/C19H20N4O3/c1-19(2,3)16-12-17(23-26-16)22-18(24)21-13-4-6-14(7-5-13)25-15-8-10-20-11-9-15/h4-12H,1-3H3,(H2,21,22,23,24)

Standard InChI Key:  XKNAGLMNQADBQE-UHFFFAOYSA-N

Alternative Forms

1. Parent:

   

   ALA166031

   1-(5-Tert-butyl-1,2-oxazol-3-YL)-3-(4-pyridin-4-yloxyphenyl)urea

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 352.39

Molecular Weight (Monoisotopic): 352.1535

AlogP: 4.80

#Rotatable Bonds: 4

Polar Surface Area: 89.28

Molecular Species: NEUTRAL

HBA: 5

HBD: 2

#RO5 Violations: ┄

HBA (Lipinski): 7

HBD (Lipinski): 2

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: 8.27

CX Basic pKa: 5.95

CX LogP: 3.83

CX LogD: 3.76

Aromatic Rings: 3

Heavy Atoms: 26

QED Weighted: 0.70

Np Likeness Score: -1.55

References

1. Khire UR, Bankston D, Barbosa J, Brittelli DR, Caringal Y, Carlson R, Dumas J, Gane T, Heald SL, Hibner B, Johnson JS, Katz ME, Kennure N, Kingery-Wood J, Lee W, Liu XG, Lowinger TB, McAlexander I, Monahan MK, Natero R, Renick J, Riedl B, Rong H, Sibley RN, Smith RA, Wolanin D..  (2004)  Omega-carboxypyridyl substituted ureas as Raf kinase inhibitors: SAR of the amide substituent.,  14  (3): [PMID:14741289] [10.1016/j.bmcl.2003.11.041]

2. Li HF, Lu T, Zhu T, Jiang YJ, Rao SS, Hu LY, Xin BT, Chen YD..  (2009)  Virtual screening for Raf-1 kinase inhibitors based on pharmacophore model of substituted ureas.,  44  (3): [PMID:18947905] [10.1016/j.ejmech.2008.09.016]

3. Collins I, Workman P..  (2006)  New approaches to molecular cancer therapeutics.,  2  (12): [PMID:17108987] [10.1038/nchembio840]

4. Charnley AK, Convery MA, Lakdawala Shah A, Jones E, Hardwicke P, Bridges A, Ouellette M, Totoritis R, Schwartz B, King BW, Wisnoski DD, Kang J, Eidam PM, Votta BJ, Gough PJ, Marquis RW, Bertin J, Casillas L..  (2015)  Crystal structures of human RIP2 kinase catalytic domain complexed with ATP-competitive inhibitors: Foundations for understanding inhibitor selectivity.,  23  (21): [PMID:26455654] [10.1016/j.bmc.2015.09.038]

5. Saha D, Ryan KR, Lakkaniga NR, Acharya B, Garcia NG, Smith EL, Frett B..  (2021)  Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development.,  64  (16.0): [PMID:34402300] [10.1021/acs.jmedchem.0c02167]

Source

Source(1):

• Scientific Literature